Trump administration drops Biden plan for Medicare to cover weight-loss drugs

Trump admin won't cover Ozempic for Medicaid, Medicare patients

The Trump administration announced it wouldnot extend Medicare Part D or Medicaid coverage to popular weight loss drugs like Ozempic. The move reverses efforts by the previous administration to classify obesity as a disease eligible for coverage. An October 2024 Congressional Budget Office report estimated that covering such medications would cost $35 billion from 2026 to 2034. The report also estimated relatively small savings from improved he…

Medicare Won’t Expand Coverage of Anti-Obesity Drugs

The Centers for Medicare and Medicaid Services (CMS) announced on April 4 that it would not start covering anti-obesity drugs for its beneficiaries. This decision was reflected in a final ruling, released the same day, that sought to modernize and improve Medicare Advantage, Medicare Prescription Drug Benefits (Part D), Medicare cost plans, and Programs of All-Inclusive Care for the Elderly. It stated that it did not intend to finalize Part D co…

Trump administration blocks Medicare from covering weight-loss medications

The injectable drugs have exploded in popularity due to the potentially life-changing weight loss that some patients experience.

The Trump administration revoked a Biden-era initiative for Medicare and Medicaid to cover anti-obesity drugs. The decision was announced as part of a 438-page regulation, updating the programs that cover the beneficiaries’ medications. Read more]]>

Trump administration abandons expanded access to anti-obesity drugs

The Trump administration has dropped a Biden-era proposal to expand coverage of costly anti-obesity drugs to Medicare and Medicaid beneficiaries.

Donald Trump rejects Biden's proposal for Medicare coverage of high-demand obesity drugs

Joe Biden had proposed a rule in late November after Trump won re-election that would have extended coverage of drugs meant for fighting obesity.